Axsome Therapeutics, Inc. (AXSM)
Largest Insider Buys in Sector
AXSM Stock Price History Chart
AXSM Stock Performance
About Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. It is also developing AXS-07, a novel, oral, rapidly …
Insider Activity of Axsome Therapeutics, Inc.
Over the last 12 months, insiders at Axsome Therapeutics, Inc. have bought $0 and sold $9.66M worth of Axsome Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Axsome Therapeutics, Inc. have bought $161,593 and sold $5.94M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 3,950 shares for transaction amount of $147,350 was made by JEFFS ROGER (director) on 2021‑11‑19.
List of Insider Buy and Sell Transactions, Axsome Therapeutics, Inc.
| 2024-09-11 | Sale | director | 11,016 0.0226% | $91.31 | $1.01M | +0.48% | ||
| 2024-08-09 | Sale | Chief Operating Officer | 47,739 0.1009% | $84.26 | $4.02M | +7.90% | ||
| 2024-05-29 | Sale | director | 5,248 0.011% | $75.14 | $394,333 | +15.02% | ||
| 2024-05-29 | Sale | Chief Operating Officer | 7,910 0.0165% | $74.31 | $587,813 | +15.02% | ||
| 2024-05-28 | Sale | director | 5,249 0.0108% | $75.21 | $394,775 | +12.50% | ||
| 2024-04-01 | Sale | Chief Operating Officer | 24,662 0.0522% | $77.24 | $1.9M | +7.30% | ||
| 2024-03-15 | Sale | director | 2,347 0.0047% | $71.61 | $168,062 | +4.70% | ||
| 2024-03-14 | Sale | director | 16,976 0.036% | $69.70 | $1.18M | +13.26% | ||
| 2023-09-15 | Sale | director | 29,588 0.0626% | $75.18 | $2.22M | -0.49% | ||
| 2021-11-19 | director | 3,950 0.0109% | $37.30 | $147,350 | +3.44% | |||
| 2021-11-18 | director | 1,430 0.0037% | $35.09 | $50,181 | +4.03% | |||
| 2021-11-18 | CHIEF FINANCIAL OFFICER | 955 0.0025% | $35.26 | $33,676 | +4.03% | |||
| 2021-11-17 | director | 3,300 0.0087% | $34.52 | $113,922 | +7.00% | |||
| 2021-05-12 | director | 500 0.0014% | $58.15 | $29,075 | -38.38% | |||
| 2020-06-29 | director | 650 0.0018% | $78.50 | $51,025 | -5.10% | |||
| 2020-06-29 | Chief Financial Officer | 777 0.0021% | $76.64 | $59,549 | -5.10% | |||
| 2019-09-26 | Chief Financial Officer | 2,180 0.0063% | $24.80 | $54,064 | +210.19% | |||
| 2019-06-26 | director | 15,800 0.0481% | $23.10 | $364,980 | +145.30% | |||
| 2019-06-25 | director | 400 0.0011% | $23.25 | $9,300 | +126.86% | |||
| 2019-06-11 | Chief Financial Officer | 1,920 0.0057% | $20.80 | $39,936 | +117.89% |
Insider Historical Profitability
| JEFFS ROGER | director | 120756 0.2516% | $90.81 | 1 | 2 | +3.44% |
| Coleman Mark | director | 14600 0.0304% | $90.81 | 7 | 3 | +51.01% |
| Saad Mark E | director | 10002 0.0208% | $90.81 | 2 | 1 | +23.86% |
| Pizzie Nick | CHIEF FINANCIAL OFFICER | 41789 0.0871% | $90.81 | 6 | 0 | +75.66% |
| Kaye Randall | Chief Medical Officer | 6022 0.0125% | $90.81 | 1 | 0 | <0.0001% |
Institutional Investor Ownership
| RTW Investments, LP | $358.52M | 9.46 | 4.49M | +0.07% | +$246,023.40 | 5.37 | |
| The Vanguard Group | $298.47M | 7.88 | 3.74M | +1.18% | +$3.47M | 0.01 | |
| BlackRock | $255M | 6.73 | 3.2M | -1.37% | -$3.53M | 0.01 | |
| Fairmount Funds Management LLC | $188.33M | 4.97 | 2.36M | 0% | +$0 | 20.53 | |
| Deep Track Capital Lp | $104.12M | 2.75 | 1.3M | +30.47% | +$24.32M | 0.48 |